Intelligence Profile
Research Papers
Deferoxamine is a medication primarily used for managing iron overload disorders. The literature on deferoxamine includes several studies related to iron metabolism and its role in various diseases.
One significant paper titled "Iron overload cardiomyopathy," published in Heart Failure Reviews, discusses the impact of iron accumulation on heart function. It suggests that excess iron can lead to cardiomyopathy, and treatments like deferoxamine may help prevent or mitigate this condition by chelating excess iron.
The study "Iron metabolism and ferroptosis in cardiovascular diseases" in Redox Biology explores the mechanisms of iron's involvement in cardiovascular diseases. It highlights the pharmacological interventions, such as deferoxamine, that target iron metabolism as a potential treatment strategy.
A completed Phase 2 clinical trial (NCT00110617) compared deferoxamine with deferasirox in sickle cell disease patients. This trial provided insights into the effectiveness and safety of different chelation therapies in managing iron overload in these patients.
Another relevant trial, though not directly involving deferoxamine, assessed the combination of deferiprone and deferoxamine (NCT00733811) to evaluate their sequential use versus deferiprone alone in iron chelation therapy. This Phase 4 trial indicated the importance of optimizing chelation strategies to improve patient outcomes.
Despite the comprehensive studies on iron metabolism and related therapies, specific new clinical data directly focusing on deferoxamine's standalone impact in various conditions remains limited, underscoring the need for ongoing research.
Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.